Difficulties in diagnosis of carcinoma of the tongue
DOI:
https://doi.org/10.15584/ejcem.2019.4.14Keywords:
hemiglossectomy, leukoplakia, PET-CT scan, radiotherapyAbstract
Introduction. Oral cancer is the second most common malignancy and there is an epidemic alert by WHO for oral cancers projected for 2030. The tongue remains the most common intraoral site for oral cancer worldwide.
Aim. To present a case report.
Description of the case. A 56-year-old patient was suffering from carcinoma of the tongue. He developed metastases in the lungs and upper part of the vertebral column. The PET scan report revealed the presence of hypermetabolic cells in the metastatic tissue. The biopsy of the lesion on the upper part of the back did not show neoplastic cells, epithelioid cells and giant cells. Radiotherapy was given for 25 cycles. Both the lungs were affected by metastases. Lastly the patient expired due to cardio-respiratory failure.
Conclusion. Tobacco is the most important known risk factor for the development of tongue cancer. The tumors in their early stage with complete excisional treatment have good prognosis. There is usually a history of long standing leukoplakia or erythroplakia. Ideally, imaging should take place prior to biopsy. Surgical procedures such as hemiglossectomy can cause functional defects in speech and swallowing. Difficulty in diagnosis results in inappropriate treatment.
Downloads
References
Petersen PE. The world oral health report 2003: Continuous improvement of oral health in the 21st century? The approach of the WHO global oral health programme. Community Dent Oral Epidemiol. 2003;31:3-24.
International Agency for Research on Cancer. Stewart BW, Kleihues P. World cancer report 2003. https://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2003. Accessed February 2, 2019.
Urken ML, Weinberg H, Vickery C, Buchbinder D, Lawson W, Biller HF. Oromandibular reconstruction using microvascular composite free flaps. Report of 71 cases and a new classification scheme for bony, soft-tissue, and neurologic defects. Arch Otolaryngol Head Neck Surg. 1991;117(7):733-744.
Nair U, Bartsch H, Nair J. Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. Mutagenesis. 2004;19(4):251.
Choi YJ, Hu Y, Mahmood A. Clinical significance of a polymerase chain reaction assay for the detection of Mycobacterium tuberculosis. Am J Clin Pathol. 1996;105(2):200-204.
Brugiere O, Vokurka M, Lecossier D, et al. Diagnosis of smear-negative pulmonary tuberculosis using sequence capture polymerase chain reaction. Am J Respir Crit Care Med. 1997;155(4):1478-1481.
Ellis MA, Graboyes EM, Wahlquist AE, et al. Primary Surgery vs Radiotherapy for Early Stage Oral Cavity Cancer. Otolaryngol Head Neck Surg. 2018;158:649.
Haughey BH, Hinni ML, Salassa JR, et al. Trans oral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck. 2011;33:1683.
Kalender W. Computed Tomography. Publicis. 2011:79
Dias FL, Lima RA, Kligerman J, et al. Relevance of skip metastases for squamous cell carcinoma of the oral tongue and the floor of the mouth. Otolaryngol Head Neck Surg. 2006;134:460.
Joseph LJ, Goodman M, Higgins K, et al. Racial disparities in squamous cell carcinoma of the oral tongue among women: a SEER data analysis. Oral Oncol. 2015;51:586.
Ridge JA, Lydiatt WM, Patel SG, et al. Lip and Oral Cavity. In: AJCC Cancer Staging Manual, 8th, Amin MB (Ed), Springer, New York 2017,79.
Luryi AL, Chen MM, Mehra S, et al. Treatment Factors Associated With Survival in Early-Stage Oral Cavity Cancer: Analysis of 6830 Cases From the National Cancer Data Base. JAMA Otolaryngol Head Neck Surg 2015;141:593.
Sinha P, Hackman T, Nussenbaum B, Wu N, Lewis JS Jr, Haughey BH. Transoral laser microsurgery for oral squamous cell carcinoma: oncologic outcomes and prognostic factors. Head Neck. 2014;36(3):340-351.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
